- Home
- EBMT vs VTVT Comparison
EBMT vs VTVT Comparison
Compare EBMT & VTVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EBMT | VTVT |
|---|---|---|
| Founded | 1922 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 132.0M | 127.0M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | EBMT | VTVT |
|---|---|---|
| Price | $19.28 | $34.17 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $37.00 |
| AVG Volume (30 Days) | ★ 37.1K | 12.6K |
| Earning Date | 01-27-2026 | 11-06-2025 |
| Dividend Yield | ★ 3.04% | N/A |
| EPS Growth | ★ 58.15 | N/A |
| EPS | ★ 1.72 | N/A |
| Revenue | ★ $87,531,000.00 | $17,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.26 | N/A |
| P/E Ratio | $11.10 | ★ N/A |
| Revenue Growth | ★ 9.36 | N/A |
| 52 Week Low | $14.35 | $13.15 |
| 52 Week High | $19.14 | $35.95 |
Technical Indicators
Market Signals| Indicator | EBMT | VTVT |
|---|---|---|
| Relative Strength Index (RSI) | 82.17 | 72.05 |
| Support Level | $16.05 | $32.84 |
| Resistance Level | $16.50 | $35.95 |
| Average True Range (ATR) | 0.35 | 2.17 |
| MACD | 0.27 | 0.67 |
| Stochastic Oscillator | 96.61 | 97.41 |
Price Performance
Historical ComparisonAbout EBMT Eagle Bancorp Montana Inc.
Eagle Bancorp Montana Inc operates as a bank holding company. It provides loan and deposit services. The company focuses on residential loans, commercial real estate loans, commercial loans, consumer loans, and home equity loan products. The bank also offers deposit accounts which include checking, savings, money market, individual retirement accounts, and certificates of deposit accounts. It is a diversified lender with a focus on residential mortgage loans, commercial real estate mortgage loans, commercial business loans, agricultural loans, and second mortgage/home equity loan products.
About VTVT vTv Therapeutics Inc.
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin, currently in a Phase 3 trial, a potential novel first-in-class oral liver-selective glucokinase activator being investigated for the treatment of type 1 diabetes. The group and its development partners are investigating multiple molecules across different indications for chronic diseases. Its product pipeline are HPP737, Azeliragon, TTP-RA, TTP273, HPP971 / HPP3033, and HPP593.